The effectiveness of mesalazine suppositories and oral doses varies from person to person, and there are some differences between the two in terms of the rate of absorption of the drug. Mesalazine suppositories are released primarily in the distal part of the intestinal tract and are poorly absorbed systemically, with about less than 10% of the dose typically being absorbed. Mesalazine enteric-coated tablets begin release after a delay of 3 to 4 hours, and about 75% of mesalazine reaches the colon in a non-metabolized form. Different patients use different medications and results vary from person to person, and it is not possible to conclude which one works better. Mesalazine suppositories are used primarily for ulcerative colitis, and mesalazine tablets may also be combined in some patients. Mesalazine suppositories are in direct contact with inflamed intestinal tissue. Rectal administration is associated with mild irritation, such as itching, rectal discomfort, and adverse reactions such as rippling. Mesalazine enteric-coated tablets are commonly used in acute exacerbations of ulcerative colitis and Crohn’s disease. It is released in the intestinal tract after oral administration and acts mainly locally on the intestinal mucosa and submucosal tissues. There may be adverse reactions such as diarrhea, nausea and dizziness. Due to the different conditions of patients, each patient’s drug treatment effect is not the same, some patients use suppository effect is obvious, some patients use oral medication effect is obvious, therefore, and can not be compared, it is recommended that patients or according to the doctor’s instructions for medication.